GENOMIC HEALTH,INC. (NASDAQ:GHDX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On January29, 2019, the Board of Directors of Genomic Health,Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Bylaws to amend Article10. Amendments, to limit the matters under the bylaws that require a supermajority vote of sixty-six and two-thirds percent.
The foregoing summary of the amendment to the Company’s Amended and Restated Bylaws is qualified in its entirety by reference to the full text of the Company’s Amended and Restated Bylaws, a copy of which is filed as Exhibit3.1 hereto and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
3.1 Amended and Restated Bylaws of the Company, as amended January29, 2019.
GENOMIC HEALTH INC Exhibit
EX-3.1 2 a19-3909_1ex3d1.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED B Y L A W S OF GENOMIC HEALTH,…
To view the full exhibit click here
About GENOMIC HEALTH,INC. (NASDAQ:GHDX)
Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.